The observed interactions between genetic variants of TPH2 and MAPK8 highlight their cooperation as putative breast-cancer risk modulators and call upon the comprehensive scrutiny of the circadian clock system and its input and output effectors in large breast-cancer cohorts. Here, TPH2 is linked to breast carcinoma.